Leerink analyst Jason Gerberry says FDA updates regarding a generic Xyrem application appear to be a net-positive for Jazz Pharmaceuticals as the FDA concurrently ruled in a citizen's petition that it will not allow generic substitutes to carve-out safety/dosing language that is patent protected. At a minimum, the analyst expects the approved generic will need to successfully litigate the Xyrem formulation and DDI patents before launching as he believes an at-risk launch against two battletested patent families would be "financial catastrophic." Gerberry reiterates an Outperform rating on Jazz's shares.